市場調査レポート

商品コード

1355048

T細胞療法の世界市場の評価：モダリティ別、治療タイプ別、適応症別、エンドユーザー別、地域別、機会、予測（2016年～2030年）

T-Cells therapy Market Assessment, By Modality, By Therapy Type, By Indication, By End-user, By Region, Opportunities and Forecast, 2016-2030F

出版日: 2023年10月03日 | 発行: Market Xcel - Markets and Data

| ページ情報: 英文 157 Pages | 納期: 3～5営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　詳細はお問い合わせください。

価格

PDF & Excel Printable (Single User License)

USD 4,500 678,015円

レポートPDFを1名の方がご利用頂けるライセンスです。レポートPDFのパスワード保護はありません。PDF内のテキスト等のコピー＆ペーストは可能です。印刷は無制限で可能です。Excelのデータがライセンスに含まれています。

PDF & Excel Printable (Corporate License)

USD 5,700 858,819円

レポートPDFを企業の１カ国の拠点のすべての方がご利用頂けるライセンスです。レポートPDFのパスワード保護はありません。PDF内のテキスト等のコピー＆ペーストは可能ですが、企業内部での利用に限定されます。ご利用に際しては、あらかじめ出版社の許諾を得る必要があります。詳細はお問合せください。印刷は可能です。Excelのデータがライセンスに含まれています。

PDF & Excel Printable (Custom Research License)

USD 8,200 1,235,494円

レポートPDFを企業の１カ国の拠点のすべての方がご利用頂けるライセンスです。レポートPDFのパスワード保護はありません。PDF内のテキスト等のコピー＆ペーストは可能です。印刷は無制限で可能です。Excelのデータがライセンスに含まれています。アナリストアワー100時間が含まれており、レポートのカスタマイズなどにご利用いただけます。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=150.67円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

世界のT細胞療法の市場規模は、2022年の33億3,000万米ドルから2030年に129億8,000万米ドルに達し、2023年～2030年の予測期間にCAGRで18.54%の成長が予測されています。

戦略的な政府投資および民間投資の増加

Tecartus、Yescarta、Kymriahが承認された後、いくつかの組織が小規模な化学療法やタンパク質ベースの治療法の開発から改変療法へとビジネスモデルを変更しました。この要素は、民間と公的機関による戦略的投資を促し、市場成長を後押ししています。T細胞療法事業体の市場競合は、製品承認の増加と生産能力の向上により、今後数年間で拡大すると予想されます。

例えば、米国FDAは2022年2月、再発または難治性の大細胞型B細胞リンパ腫（LBCL）を管理するための初のキメラ抗原受容体（CAR）T細胞治療薬であるYescartaを承認しました。NCCN治療ガイドラインのカテゴリ1推奨により、YescartaはCAR-T細胞治療薬として初めてこの栄誉に輝きました。FDAは同様に2022年2月に、治療効果が得られなかった難治性多発性骨髄腫患者、または治療後に再発した多発性骨髄腫患者（再発）を対象に、シルタカブタゲンオートロイセル（Carvykti）を承認しています。

California Institute for Regenerative Medicine（CIRM）は2023年1月、リンパ腫や白血病を含む多様なB細胞悪性腫瘍を治療するCAR-T細胞療法の開発および試験に400万米ドルを拠出しました。

CAR-T細胞療法の進歩

CAR-T細胞療法では、患者から採取したT細胞を人工的に生物工学的な操作を加え、CARを発現させます。CAR-T細胞部門の企業は、提携、事業拡大、合意、共同研究、新製品の導入など、他社との戦略的提携を進めており、これがT細胞療法市場の成長を促進しています。

例えば、Janssen Biotech, Inc. が製造するCARVYKTIは2022年にFDAに認可されました。キメラ抗原受容体T細胞（CAR-T）は、CARVYKTIとして知られる治療法の略称です。骨髄悪性腫瘍である多発性骨髄腫の成人患者は、CARVYKTI（シルタカブタゲンオートロイセル）による治療を受けることができます。CARVYKTIは、4種類以上の前治療の後、再発または治療抵抗性を示した多発性骨髄腫の成人患者を治療します。本薬は、プロテアソーム阻害薬、免疫調節薬、抗CD38モノクローナル抗体から構成されます。

治療アプローチにおける最新の進歩

世界のT細胞療法市場は近年大きな進歩を示しています。CAR-T療法のような革新的技術はがん治療に革命をもたらし、研究者たちはTCR療法のような次世代のT細胞療法を探求しており、治療可能な疾患の範囲を広げています。さらに、健康なドナーに由来する同種T細胞療法の開発は、治療をより身近なものにしています。これらのブレークスルーは、個別化されたT細胞療法と既製のT細胞療法の有望な未来を意味し、世界市場における治療オプションの地平を広げています。

COVID-19の影響

COVID-19の発生は、世界の医療産業、特にT細胞療法市場の活動を妨げました。パンデミックは、ほとんどの国がロックダウン政策を実施したため、世界のT細胞療法市場に打撃を与えました。サプライチェーンの中断により、一部の企業ではT細胞治療薬の生産と供給に遅れが生じました。パンデミックは、いくつかのT細胞療法の臨床試験に大きな混乱をもたらし、一部の臨床試験は延期されたり、完全に中止されたりしました。

しかし、パンデミック後、がん患者の増加により医療産業におけるイノベーションの必要性が注目され、多くの企業が研究開発への取り組みを強化していることが指摘されました。そのため、T細胞療法をウイルス感染症の治療に応用する方法を解明することを目的とした研究への資金援助が奨励されています。例えば、Tevogen Bioは2022年11月、研究中のCOVID-19のT細胞療法であるTVGN-489の治療利用の可能性を検討する意向を発表しました。

当レポートでは、世界のT細胞療法市場について調査分析し、市場規模と予測、市場力学、主要企業の情勢と見通しなどを提供しています。

市場規模と予測
- 金額
モダリティ別
- 研究
- 商業化
治療タイプ別
- CAR-T細胞療法
- T細胞受容体（TCR）ベース
- 腫瘍浸潤リンパ球（TIL）ベース
適応症別
- 血液腫瘍
- 固形腫瘍
- その他
エンドユーザー別
- 病院
- がん治療センター
地域別
- 北米
- 欧州
- アジア太平洋
- 南米
- 中東・アフリカ
市場シェア：企業別（2022年）

第6章世界のT細胞療法市場の見通し：地域別（2016年～2030年）

北米
- 市場規模と予測
- モダリティ別
- 治療タイプ別
- 適応症別
- エンドユーザー別
- 米国
- カナダ
- メキシコ
欧州
- ドイツ
- フランス
- イタリア
- 英国
- ロシア
- オランダ
- スペイン
- トルコ
- ポーランド
南米
- ブラジル
- メキシコ
- アルゼンチン
アジア太平洋
- インド
- 中国
- 日本
- オーストラリア
- ベトナム
- 韓国
- インドネシア
- フィリピン
中東・アフリカ
- サウジアラビア
- アラブ首長国連邦
- 南アフリカ

第7章市場マッピング（2022年）

コンポーネント別
技術別
エンドユーザー別
製品別
地域別

第8章マクロ環境と産業構造

需給分析
輸出入の分析 - 数量と金額
サプライ/バリューチェーン分析
PESTEL分析
ポーターのファイブフォース分析

第9章市場力学

成長促進要因
成長抑制要因（課題、抑制要因）

第10章規制の枠組みとイノベーション

臨床試験
特許の情勢
規制当局の承認
イノベーション/新技術

第11章主要企業情勢

マーケットリーダー上位5社の競合マトリクス
マーケットリーダー上位5社市場の収益分析（2022年）
合併と買収/合弁事業（該当する場合）
SWOT分析（市場参入企業5社向け）
特許分析（該当する場合）

第12章価格分析

第13章ケーススタディ

第14章主要企業の見通し

Novartis AG
Merck KGaA
Gilead Sciences Inc.
TCR2 Therapeutics Inc
Bluebird Bio Inc.
Sorrento Therapeutics
Fate Therapeutics
Pfizer Inc.
Amgen
Celgene Corporation

第15章戦略的推奨事項

第16章当社について、免責事項

図表

List of Tables

Table 1. Pricing Analysis of Products from Key Players
Table 2. Competition Matrix of Top 5 Market Leaders
Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

Figure 1. Global T-Cells Therapy Market, By Value, In USD Billion, 2016-2030F
Figure 2. Global T-Cells Therapy Market Share, By Modality, In USD Billion, 2016-2030F
Figure 3. Global T-Cells Therapy Market Share, By Therapy Type, In USD Billion, 2016-2030F
Figure 4. Global T-Cells Therapy Market Share, By Indication, In USD Billion, 2016-2030F
Figure 5. Global T-Cells Therapy Market Share, By End-user, In USD Billion, 2016-2030F
Figure 6. Global T-Cells Therapy Market Share, By Region, In USD Billion, 2016-2030F
Figure 7. North America T-Cells Therapy Market, By Value, In USD Billion, 2016-2030F
Figure 8. North America T-Cells Therapy Market Share, By Modality, In USD Billion, 2016-2030F
Figure 9. North America T-Cells Therapy Market Share, By Therapy Type, In USD Billion, 2016-2030F
Figure 10. North America T-Cells Therapy Market Share, By Indication, In USD Billion, 2016-2030F
Figure 11. North America T-Cells Therapy Market Share, By End-user, In USD Billion, 2016-2030F
Figure 12. North America T-Cells Therapy Market Share, By Country, In USD Billion, 2016-2030F
Figure 13. United States T-Cells Therapy Market, By Value, In USD Billion, 2016-2030F
Figure 14. United States T-Cells Therapy Market Share, By Modality, In USD Billion, 2016-2030F
Figure 15. United States T-Cells Therapy Market Share, By Therapy Type, In USD Billion, 2016-2030F
Figure 16. United States T-Cells Therapy Market Share, By Indication, In USD Billion, 2016-2030F
Figure 17. United States T-Cells Therapy Market Share, By End-user, In USD Billion, 2016-2030F
Figure 18. Canada T-Cells Therapy Market, By Value, In USD Billion, 2016-2030F
Figure 19. Canada T-Cells Therapy Market Share, By Modality, In USD Billion, 2016-2030F
Figure 20. Canada T-Cells Therapy Market Share, By Therapy Type, In USD Billion, 2016-2030F
Figure 21. Canada T-Cells Therapy Market Share, By Indication, In USD Billion, 2016-2030F
Figure 22. Canada T-Cells Therapy Market Share, By End-user, In USD Billion, 2016-2030F
Figure 23. Mexico T-Cells Therapy Market, By Value, In USD Billion, 2016-2030F
Figure 24. Mexico T-Cells Therapy Market Share, By Modality, In USD Billion, 2016-2030F
Figure 25. Mexico T-Cells Therapy Market Share, By Therapy Type, In USD Billion, 2016-2030F
Figure 26. Mexico T-Cells Therapy Market Share, By Indication, In USD Billion, 2016-2030F
Figure 27. Mexico T-Cells Therapy Market Share, By End-user, In USD Billion, 2016-2030F
Figure 28. Europe T-Cells Therapy Market, By Value, In USD Billion, 2016-2030F
Figure 29. Europe T-Cells Therapy Market Share, By Modality, In USD Billion, 2016-2030F
Figure 30. Europe T-Cells Therapy Market Share, By Therapy Type, In USD Billion, 2016-2030F
Figure 31. Europe T-Cells Therapy Market Share, By Indication, In USD Billion, 2016-2030F
Figure 32. Europe T-Cells Therapy Market Share, By End-user, In USD Billion, 2016-2030F
Figure 33. Europe T-Cells Therapy Market Share, By Country, In USD Billion, 2016-2030F
Figure 34. Germany T-Cells Therapy Market, By Value, In USD Billion, 2016-2030F
Figure 35. Germany T-Cells Therapy Market Share, By Modality, In USD Billion, 2016-2030F
Figure 36. Germany T-Cells Therapy Market Share, By Therapy Type, In USD Billion, 2016-2030F
Figure 37. Germany T-Cells Therapy Market Share, By Indication, In USD Billion, 2016-2030F
Figure 38. Germany T-Cells Therapy Market Share, By End-user, In USD Billion, 2016-2030F
Figure 39. France T-Cells Therapy Market, By Value, In USD Billion, 2016-2030F
Figure 40. France T-Cells Therapy Market Share, By Modality, In USD Billion, 2016-2030F
Figure 41. France T-Cells Therapy Market Share, By Therapy Type, In USD Billion, 2016-2030F
Figure 42. France T-Cells Therapy Market Share, By Indication, In USD Billion, 2016-2030F
Figure 43. France T-Cells Therapy Market Share, By End-user, In USD Billion, 2016-2030F
Figure 44. Italy T-Cells Therapy Market, By Value, In USD Billion, 2016-2030F
Figure 45. Italy T-Cells Therapy Market Share, By Modality, In USD Billion, 2016-2030F
Figure 46. Italy T-Cells Therapy Market Share, By Therapy Type, In USD Billion, 2016-2030F
Figure 47. Italy T-Cells Therapy Market Share, By Indication, In USD Billion, 2016-2030F
Figure 48. Italy T-Cells Therapy Market Share, By End-user, In USD Billion, 2016-2030F
Figure 49. United Kingdom T-Cells Therapy Market, By Value, In USD Billion, 2016-2030F
Figure 50. United Kingdom T-Cells Therapy Market Share, By Modality, In USD Billion, 2016-2030F
Figure 51. United Kingdom T-Cells Therapy Market Share, By Therapy Type, In USD Billion, 2016-2030F
Figure 52. United Kingdom T-Cells Therapy Market Share, By Indication, In USD Billion, 2016-2030F
Figure 53. United Kingdom T-Cells Therapy Market Share, By End-user, In USD Billion, 2016-2030F
Figure 54. Russia T-Cells Therapy Market, By Value, In USD Billion, 2016-2030F
Figure 55. Russia T-Cells Therapy Market Share, By Modality, In USD Billion, 2016-2030F
Figure 56. Russia T-Cells Therapy Market Share, By Therapy Type, In USD Billion, 2016-2030F
Figure 57. Russia T-Cells Therapy Market Share, By Indication, In USD Billion, 2016-2030F
Figure 58. Russia T-Cells Therapy Market Share, By End-user, In USD Billion, 2016-2030F
Figure 59. Netherlands T-Cells Therapy Market, By Value, In USD Billion, 2016-2030F
Figure 60. Netherlands T-Cells Therapy Market Share, By Modality, In USD Billion, 2016-2030F
Figure 61. Netherlands T-Cells Therapy Market Share, By Therapy Type, In USD Billion, 2016-2030F
Figure 62. Netherlands T-Cells Therapy Market Share, By Indication, In USD Billion, 2016-2030F
Figure 63. Netherlands T-Cells Therapy Market Share, By End-user, In USD Billion, 2016-2030F
Figure 64. Spain T-Cells Therapy Market, By Value, In USD Billion, 2016-2030F
Figure 65. Spain T-Cells Therapy Market Share, By Modality, In USD Billion, 2016-2030F
Figure 66. Spain T-Cells Therapy Market Share, By Therapy Type, In USD Billion, 2016-2030F
Figure 67. Spain T-Cells Therapy Market Share, By Indication, In USD Billion, 2016-2030F
Figure 68. Spain T-Cells Therapy Market Share, By End-user, In USD Billion, 2016-2030F
Figure 69. Turkey T-Cells Therapy Market, By Value, In USD Billion, 2016-2030F
Figure 70. Turkey T-Cells Therapy Market Share, By Modality, In USD Billion, 2016-2030F
Figure 71. Turkey T-Cells Therapy Market Share, By Therapy Type, In USD Billion, 2016-2030F
Figure 72. Turkey T-Cells Therapy Market Share, By Indication, In USD Billion, 2016-2030F
Figure 73. Turkey T-Cells Therapy Market Share, By End-user, In USD Billion, 2016-2030F
Figure 74. Poland T-Cells Therapy Market, By Value, In USD Billion, 2016-2030F
Figure 75. Poland T-Cells Therapy Market Share, By Modality, In USD Billion, 2016-2030F
Figure 76. Poland T-Cells Therapy Market Share, By Therapy Type, In USD Billion, 2016-2030F
Figure 77. Poland T-Cells Therapy Market Share, By Indication, In USD Billion, 2016-2030F
Figure 78. Poland T-Cells Therapy Market Share, By End-user, In USD Billion, 2016-2030F
Figure 79. South America T-Cells Therapy Market, By Value, In USD Billion, 2016-2030F
Figure 80. South America T-Cells Therapy Market Share, By Modality, In USD Billion, 2016-2030F
Figure 81. South America T-Cells Therapy Market Share, By Therapy Type, In USD Billion, 2016-2030F
Figure 82. South America T-Cells Therapy Market Share, By Indication, In USD Billion, 2016-2030F
Figure 83. South America T-Cells Therapy Market Share, By End-user, In USD Billion, 2016-2030F
Figure 84. South America T-Cells Therapy Market Share, By Country, In USD Billion, 2016-2030F
Figure 85. Brazil T-Cells Therapy Market, By Value, In USD Billion, 2016-2030F
Figure 86. Brazil T-Cells Therapy Market Share, By Modality, In USD Billion, 2016-2030F
Figure 87. Brazil T-Cells Therapy Market Share, By Therapy Type, In USD Billion, 2016-2030F
Figure 88. Brazil T-Cells Therapy Market Share, By Indication, In USD Billion, 2016-2030F
Figure 89. Brazil T-Cells Therapy Market Share, By End-user, In USD Billion, 2016-2030F
Figure 90. Argentina T-Cells Therapy Market, By Value, In USD Billion, 2016-2030F
Figure 91. Argentina T-Cells Therapy Market Share, By Modality, In USD Billion, 2016-2030F
Figure 92. Argentina T-Cells Therapy Market Share, By Therapy Type, In USD Billion, 2016-2030F
Figure 93. Argentina T-Cells Therapy Market Share, By Indication, In USD Billion, 2016-2030F
Figure 94. Argentina T-Cells Therapy Market Share, By End-user, In USD Billion, 2016-2030F
Figure 95. Asia-Pacific T-Cells Therapy Market, By Value, In USD Billion, 2016-2030F
Figure 96. Asia-Pacific T-Cells Therapy Market Share, By Modality, In USD Billion, 2016-2030F
Figure 97. Asia-Pacific T-Cells Therapy Market Share, By Therapy Type, In USD Billion, 2016-2030F
Figure 98. Asia-Pacific T-Cells Therapy Market Share, By Indication, In USD Billion, 2016-2030F
Figure 99. Asia- Pacific Cream Market Share, By End-user, In USD Billion, 2016-2030F
Figure 100. Asia-Pacific T-Cells Therapy Market Share, By Country, In USD Billion, 2016-2030F
Figure 101. India T-Cells Therapy Market, By Value, In USD Billion, 2016-2030F
Figure 102. India T-Cells Therapy Market Share, By Modality, In USD Billion, 2016-2030F
Figure 103. India T-Cells Therapy Market Share, By Therapy Type, In USD Billion, 2016-2030F
Figure 104. India T-Cells Therapy Market Share, By Indication, In USD Billion, 2016-2030F
Figure 105. India T-Cells Therapy Market Share, By End-user, In USD Billion, 2016-2030F
Figure 106. China T-Cells Therapy Market, By Value, In USD Billion, 2016-2030F
Figure 107. China T-Cells Therapy Market Share, By Modality, In USD Billion, 2016-2030F
Figure 108. China T-Cells Therapy Market Share, By Therapy Type, In USD Billion, 2016-2030F
Figure 109. China T-Cells Therapy Market Share, By Indication, In USD Billion, 2016-2030F
Figure 110. China T-Cells Therapy Market Share, By End-user, In USD Billion, 2016-2030F
Figure 111. Japan T-Cells Therapy Market, By Value, In USD Billion, 2016-2030F
Figure 112. Japan T-Cells Therapy Market Share, By Modality, In USD Billion, 2016-2030F
Figure 113. Japan T-Cells Therapy Market Share, By Therapy Type, In USD Billion, 2016-2030F
Figure 114. Japan T-Cells Therapy Market Share, By Indication, In USD Billion, 2016-2030F
Figure 115. Japan T-Cells Therapy Market Share, By End-user, In USD Billion, 2016-2030F
Figure 116. Australia T-Cells Therapy Market, By Value, In USD Billion, 2016-2030F
Figure 117. Australia T-Cells Therapy Market Share, By Modality, In USD Billion, 2016-2030F
Figure 118. Australia T-Cells Therapy Market Share, By Therapy Type, In USD Billion, 2016-2030F
Figure 119. Australia T-Cells Therapy Market Share, By Indication, In USD Billion, 2016-2030F
Figure 120. Australia T-Cells Therapy Market Share, By End-user, In USD Billion, 2016-2030F
Figure 121. Vietnam T-Cells Therapy Market, By Value, In USD Billion, 2016-2030F
Figure 122. Vietnam T-Cells Therapy Market Share, By Modality, In USD Billion, 2016-2030F
Figure 123. Vietnam T-Cells Therapy Market Share, By Therapy Type, In USD Billion, 2016-2030F
Figure 124. Vietnam T-Cells Therapy Market Share, By Indication, In USD Billion, 2016-2030F
Figure 125. Vietnam T-Cells Therapy Market Share, By End-user, In USD Billion, 2016-2030F
Figure 126. South Korea T-Cells Therapy Market, By Value, In USD Billion, 2016-2030F
Figure 127. South Korea T-Cells Therapy Market Share, By Modality, In USD Billion, 2016-2030F
Figure 128. South Korea T-Cells Therapy Market Share, By Therapy Type, In USD Billion, 2016-2030F
Figure 129. South Korea T-Cells Therapy Market Share, By Indication, In USD Billion, 2016-2030F
Figure 130. South Korea T-Cells Therapy Market Share, By End-user, In USD Billion, 2016-2030F
Figure 131. Indonesia T-Cells Therapy Market, By Value, In USD Billion, 2016-2030F
Figure 132. Indonesia T-Cells Therapy Market Share, By Modality, In USD Billion, 2016-2030F
Figure 133. Indonesia T-Cells Therapy Market Share, By Therapy Type, In USD Billion, 2016-2030F
Figure 134. Indonesia T-Cells Therapy Market Share, By Indication, In USD Billion, 2016-2030F
Figure 135. Indonesia T-Cells Therapy Market Share, By End-user, In USD Billion, 2016-2030F
Figure 136. Philippines T-Cells Therapy Market, By Value, In USD Billion, 2016-2030F
Figure 137. Philippines T-Cells Therapy Market Share, By Modality, In USD Billion, 2016-2030F
Figure 138. Philippines T-Cells Therapy Market Share, By Therapy Type, In USD Billion, 2016-2030F
Figure 139. Philippines T-Cells Therapy Market Share, By Indication, In USD Billion, 2016-2030F
Figure 140. Philippines T-Cells Therapy Market Share, By End-user, In USD Billion, 2016-2030F
Figure 141. Middle East & Africa T-Cells Therapy Market, By Value, In USD Billion, 2016-2030F
Figure 142. Middle East & Africa T-Cells Therapy Market Share, By Modality, In USD Billion, 2016-2030F
Figure 143. Middle East & Africa T-Cells Therapy Market Share, By Therapy Type, In USD Billion, 2016-2030F
Figure 144. Middle East & Africa T-Cells Therapy Market Share, By Indication, In USD Billion, 2016-2030F
Figure 145. Middle East & Africa T-Cells Therapy Market Share, By End-user, In USD Billion, 2016-2030F
Figure 146. Middle East & Africa T-Cells Therapy Market Share, By Country, In USD Billion, 2016-2030F
Figure 147. Saudi Arabia T-Cells Therapy Market, By Value, In USD Billion, 2016-2030F
Figure 148. Saudi Arabia T-Cells Therapy Market Share, By Modality, In USD Billion, 2016-2030F
Figure 149. Saudi Arabia T-Cells Therapy Market Share, By Therapy Type, In USD Billion, 2016-2030F
Figure 150. Saudi Arabia T-Cells Therapy Market Share, By Indication, In USD Billion, 2016-2030F
Figure 151. Saudi Arabia T-Cells Therapy Market Share, By End-user, In USD Billion, 2016-2030F
Figure 152. UAE T-Cells Therapy Market, By Value, In USD Billion, 2016-2030F
Figure 153. UAE T-Cells Therapy Market Share, By Modality, In USD Billion, 2016-2030F
Figure 154. UAE T-Cells Therapy Market Share, By Therapy Type, In USD Billion, 2016-2030F
Figure 155. UAE T-Cells Therapy Market Share, By Indication, In USD Billion, 2016-2030F
Figure 156. UAE T-Cells Therapy Market Share, By End-user, In USD Billion, 2016-2030F
Figure 157. South Africa T-Cells Therapy Market, By Value, In USD Billion, 2016-2030F
Figure 158. South Africa T-Cells Therapy Market Share, By Modality, In USD Billion, 2016-2030F
Figure 159. South Africa T-Cells Therapy Market Share, By Therapy Type, In USD Billion, 2016-2030F
Figure 160. South Africa T-Cells Therapy Market Share, By Indication, In USD Billion, 2016-2030F
Figure 161. South Africa T-Cells Therapy Market Share, By End-user, In USD Billion, 2016-2030F
Figure 162. By Modality Map-Market Size (USD Billion) & Growth Rate (%), 2022
Figure 163. By Therapy Type Map-Market Size (USD Billion) & Growth Rate (%), 2022
Figure 164. By Indication Map-Market Size (USD Billion) & Growth Rate (%), 2022
Figure 165. By End-user Map-Market Size (USD Billion) & Growth Rate (%), 2022
Figure 166. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2022

Product Code: MX10500

Global T-Cells therapy market size was valued at USD 3.33 billion in 2022, and is expected to reach USD 12.98 billion in 2030, with a CAGR of 18.54% for the forecast period between 2023 and 2030F. The market for T-cell treatment is constantly evolving and expanding, largely due to ongoing research and development initiatives. To improve efficacy and widen the applications of T-cell therapies, scientists and researchers are constantly investigating new methods, tools, and therapeutic targets. The key factors driving the expansion of the T-cell therapy market size are the rise in cancer prevalence, elderly population, and the usage of various cell therapy technologies to treat cancer symptoms. The prevalence of certain cancers such as leukemia, myeloma, lymphoma, and cancer relapse increase the need for efficient therapeutic interventions and fuels market growth. Also, multiple medications that are currently in the clinical development stage are fueling the market's expansion. For instance, Caribou Biosciences, Inc.'s CB-010 and CB-011 are undergoing phase I clinical studies. Similarly, Cartesian Therapeutics, Inc.'s DESCARTES-17 and DESCARTES-25 are now undergoing preclinical and Phase I trials, respectively. Thus, it is further projected that key companies' attention to developments may possibly fuel the market for T-cell treatment growth.

Increased Strategic Government and Private Investments

After tecartus, Yescarta, and Kymriah were approved, several organizations changed their business models from developing small chemical and protein-based treatments to adoptive therapy. This element has encouraged strategic investments by both private and public organizations, which has helped the market grow. The market rivalry for T-cell therapy entities is anticipated to expand in the coming years due to increasing product approval and rising production capacities.

For instance, the U.S. FDA approved Yescarta, the first chimeric antigen receptor (CAR) T-cell treatment in February 2022 to manage relapsed or refractory large B-cell lymphoma (LBCL). The NCCN Treatment Guideline's Category 1 recommendation for Yescarta makes it the first CAR T-cell treatment to receive this distinction. The FDA similarly approved ciltacabtagene autoleucel (Carvykti) in February 2022 for patients with multiple myeloma that is refractory, which did not respond to treatment, or has reappeared after treatment (relapsed).

The California Institute for Regenerative Medicine (CIRM) committed $4 million in January 2023 to develop and test a CAR T-cell therapy for treating diverse B-cell malignancies, including lymphomas and leukemias.

Following the closure of the transaction in May 2023 , Laurus Labs' share in ImmunoACT will rise to 33.86% on a fully diluted basis. In November 2021, the corporation had already purchased 26.62% of ImmunoACT. The CAR T-cell therapy assets in ImmunoACT's portfolio are in various stages of development and are used to treat various cancers and autoimmune illnesses. With this funding, Laurus Labs is more committed to offering patients revolutionary Cell and Gene Therapy technology at an affordable price. This funding will aid ImmunoACT in preparing to produce more medications.

Advancement in CAR T-Cell Therapy

In CAR T-cell therapy, T-cells taken from patients are artificially bioengineered to express CARS, which can recognize and attach to the cancer cells. Companies in the CAR T-cell segment are engaging in strategic developments with other companies, such as partnerships, expansions, agreements, collaborations, and the introduction of new products, which is promoting the growth of the T-cell treatment market.

For instance, the FDA authorized CARVYKTI produced by Janssen Biotech, Inc. in 2022. Chimeric antigen receptor T-cell, or CAR-T, is the abbreviation for the therapy known as CARVYKTI. Adult patients with multiple myeloma, a bone marrow malignancy, can receive treatment with CARVYKTI (ciltacabtagene autoleucel). After four or more prior lines of therapy, CARVYKTI treats adult patients with multiple myeloma that have relapsed or become resistant to treatment. It comprises a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 monoclonal antibody.

Astellas committed USD 50 million to Poseida's CAR T-cell therapy in August 2023. Astellas will have exclusive negotiating rights and first choice for licensing P-MUC1C-ALLO1 in solid tumors as part of the agreement.

Government Regulations

The development, testing, and marketing of cell therapies and other biologics used in T-cell therapy treatments, such as adoptive cell transfer (ACT), are governed by the U.S. Food and Drug Administration (FDA).

Cell therapy evaluation standards and guidelines have been published by the European Medicines Agency (EMA) for use in clinical and human trials.

The safety, effectiveness, and quality of biological products used in T-cell therapy treatments are overseen by the FDA's Center for Biologic Evaluation and Research (CBER).

Best practices have been established by the National Institutes of Health (NIH ) for carrying out clinical trials utilizing cell therapies, particularly for T-cell therapy. Guidelines for patient selection criteria, risk assessment techniques, and monitoring procedures are included.

To guarantee that cell therapies are produced safely and ethically, the International Society for Cellular Therapy (ISCT) offers rules and criteria.

Latest Advancements in Therapeutic Approaches

The global T-cell therapy market has witnessed significant advancements in recent years. Innovative technologies like CAR-T therapy have revolutionized cancer treatment, researchers are exploring next-generation T-cell therapies, such as TCR (T-cell Receptor) therapies, which broadens the scope of treatable diseases. Furthermore, the development of allogeneic T-cell therapies, derived from healthy donors, is making treatments more accessible. These breakthroughs signify a promising future for personalized and off-the-shelf T-cell therapies, expanding the horizon of therapeutic options in the global market.

The U.S. Food and Drug Administration (FDA) granted the Regenerative Medicine Advanced Therapy (RMAT) designation to Autolus Therapeutics plc, a clinical-stage biopharmaceutical firm, to its lead gene therapy obecabatagene autoleucel (obe-cel) in April 2022. In the ongoing FELIX Phase 2 study in adult relapsed/refractory B-Acute Lymphocytic Leukemia, a CD19-directed autologous chimeric antigen receptor (CAR) T treatment is being examined.

In 2022, Novartis International AG introduced a novel T-Cell Therapy known as Kymriah, specifically designed for addressing relapsed or refractory follicular lymphoma. This innovative therapy, classified as a CD19-targeted CAR-T-cell therapy, received FDA approval.

Impact of COVID-19

The COVID-19 outbreak hampered operations in the global health care industry, especially the T-cell treatment market. The pandemic hurt the global T-cell treatment market since most nations implemented lockdown policies. Due to supply chain interruptions, certain businesses encountered delays in producing and delivering T-cell therapies. The pandemic caused significant disruptions to several clinical trials of T-cell treatments, with some trials being postponed or discontinued entirely.

However, it was noted that post-pandemic, the prevalence of cancer cases has brought attention to the need for innovation in the healthcare industry, and many businesses are boosting their efforts in R&D. It has encouraged funding for research aimed at figuring out how T-cell treatments might be applied to treat viral infections. For instance, Tevogen Bio announced, in November 2022, it intended to examine the potential therapeutic uses of TVGN-489, an investigational COVID-19 T-cell therapy, in Long COVID. The highly purified cytotoxic CD8+ T lymphocytes (CTLs) TVGN-489 are designed to locate and eradicate SARS-CoV-2 infected cells.

Key Players Landscape and Outlook

The increasing number of businesses engaging in CAR-T therapy development is projected to boost market competition. Novartis AG and Kite Pharma currently dominate the T-cell therapy market through innovative and novel product introductions. In addition, numerous prominent corporations are launching significant initiatives to strengthen their market presence. For instance, in June 2022, Immunocore Ltd., a commercial-stage biotechnology startup, engaged into a clinical trial collaboration and supply deal with Sanofi. Sanofi can use KIMMTRAK to analyze their precisely PEGylated, tailored form of IL-2, SAR444245 in this collaboration. The agreement will help the company's expansion by improving cell therapy manufacturing operations.

1. Research Methodology

2. Project Scope & Definitions

3. Impact of COVID-19 on the Global T-Cells Therapy Market

4. Executive Summary

5. Global T-Cells Therapy Market Outlook, 2016-2030F

5.1. Market Size & Forecast
- 5.1.1 By Value
5.2. By Modality
- 5.2.1. Research
- 5.2.2. Commercialized
5.3. By Therapy Type
- 5.3.1. CAR T-cell Therapy
- 5.3.2. T-Cell Receptor (TCR)-based
- 5.3.3. Tumor Infiltrating Lymphocytes (TIL)-based
5.4. By Indication
- 5.4.1. Hematologic Malignancies
  - 5.4.1.1. Lymphoma
  - 5.4.1.2. Leukemia
  - 5.4.1.3. Myeloma
- 5.4.2. Solid Tumors
  - 5.4.2.1. Melanoma
  - 5.4.2.2. Brain & Central Nervous System
  - 5.4.2.3. Liver Cancer
  - 5.4.2.4. Others
- 5.4.3. Others
5.5. By End-user
- 5.5.1. Hospitals
- 5.5.2. Cancer Treatment Centers
5.6. By Region
- 5.6.1. North America
- 5.6.2. Europe
- 5.6.3. Asia Pacific
- 5.6.4. South America
- 5.6.5. Middle East & Africa
5.7. By Company Market Share (%), 2022

6. Global T-Cells Therapy Market Outlook, By Region, 2016-2030F

6.2. North America*
- 6.2.1. Market Size & Forecast
  - 6.2.1.1. By Value
- 6.2.2. By Modality
  - 6.2.2.1. Research
  - 6.2.2.2. Commercialized
- 6.2.3. By Therapy Type
  - 6.2.3.1. CAR T-cell Therapy
  - 6.2.3.2. T-Cell Receptor (TCR)-based
  - 6.2.3.3. Tumor Infiltrating Lymphocytes (TIL)-based
- 6.2.4. By Indication
  - 6.2.4.1. Hematologic Malignancies
  - 6.2.4.1.1. Lymphoma
  - 6.2.4.1.2. Leukemia
  - 6.2.4.1.3. Myeloma
  - 6.2.4.2. Solid Tumors
  - 6.2.4.2.1. Melanoma
  - 6.2.4.2.2. Brain & Central Nervous System
  - 6.2.4.2.3. Liver Cancer
  - 6.2.4.2.4. Others
- 6.2.5. By End-user
  - 6.2.5.1. Hospitals
  - 6.2.5.2. Cancer Treatment Centers
- 6.2.6. United States*
  - 6.2.6.1. Market Size & Forecast
  - 6.2.6.1.1. By Value
  - 6.2.6.2. By Therapy Type
  - 6.2.6.2.1. CAR T-cell Therapy
  - 6.2.6.2.2. T-Cell Receptor (TCR)-based
  - 6.2.6.2.3. Tumor Infiltrating Lymphocytes (TIL)-based
  - 6.2.6.3. By Indication
  - 6.2.6.3.1. Hematologic Malignancies
  - 6.2.6.3.1.1. Lymphoma
  - 6.2.6.3.1.2. Leukemia
  - 6.2.6.3.1.3. Myeloma
  - 6.2.6.3.2. Solid Tumors
  - 6.2.6.3.2.1. Melanoma
  - 6.2.6.3.2.2. Brain & Central Nervous System
  - 6.2.6.3.2.3. Liver Cancer
  - 6.2.6.3.2.4. Others
  - 6.2.6.4. By End-user
  - 6.2.6.4.1. Hospitals
  - 6.2.6.4.2. Cancer Treatment Centers
- 6.2.7. Canada
- 6.2.8. Mexico

All segments will be provided for all regions and countries covered:

6.3. Europe
- 6.3.1. Germany
- 6.3.2. France
- 6.3.3. Italy
- 6.3.4. United Kingdom
- 6.3.5. Russia
- 6.3.6. Netherlands
- 6.3.7. Spain
- 6.3.8. Turkey
- 6.3.9. Poland
6.4. South America
- 6.4.1. Brazil
- 6.4.2. Mexico
- 6.4.3. Argentina
6.5. Asia-Pacific
- 6.5.1. India
- 6.5.2. China
- 6.5.3. Japan
- 6.5.4. Australia
- 6.5.5. Vietnam
- 6.5.6. South Korea
- 6.5.7. Indonesia
- 6.5.8. Philippines
6.6. Middle East & Africa
- 6.6.1. Saudi Arabia
- 6.6.2. UAE
- 6.6.3. South Africa

7. Market Mapping, 2022

7.2. By Component
7.3. By Technology
7.4. By End-user
7.5. By Product
7.6. By Region

8. Macro Environment and Industry Structure

8.2. Supply Demand Analysis
8.3. Import Export Analysis - Volume and Value
8.4. Supply/Value Chain Analysis
8.5. PESTEL Analysis
- 8.5.1. Political Factors
- 8.5.2. Economic System
- 8.5.3. Social Implications
- 8.5.4. Technological Advancements
- 8.5.5. Environmental Impacts
- 8.5.6. Legal Compliances and Regulatory Policies (Statutory Bodies Included)
8.6. Porter's Five Forces Analysis
- 8.6.1. Supplier Power
- 8.6.2. Buyer Power
- 8.6.3. Substitution Threat
- 8.6.4. Threat from New Entrant
- 8.6.5. Competitive Rivalry

9. Market Dynamics

9.2. Growth Drivers
9.3. Growth Inhibitors (Challenges, Restraints)

10. Regulatory Framework and Innovation

10.2. Clinical Trials
10.3. Patent Landscape
10.4. Regulatory Approvals
10.5. Innovations/Emerging Technologies

11. Key Players Landscape

11.2. Competition Matrix of Top Five Market Leaders
11.3. Market Revenue Analysis of Top Five Market Leaders (in %, 2022)
11.4. Mergers and Acquisitions/Joint Ventures (If Applicable)
11.5. SWOT Analysis (For Five Market Players)
11.6. Patent Analysis (If Applicable)

12. Pricing Analysis

13. Case Studies

14. Key Players Outlook

14.2. Novartis AG
- 14.2.1. Company Details
- 14.2.2. Key Management Personnel
- 14.2.3. Products & Services
- 14.2.4. Financials (As reported)
- 14.2.5. Key Market Focus & Geographical Presence
- 14.2.6. Recent Developments
14.3. Merck KGaA
14.4. Gilead Sciences Inc.
14.5. TCR2 Therapeutics Inc
14.6. Bluebird Bio Inc.
14.7. Sorrento Therapeutics
14.8. Fate Therapeutics
14.9. Pfizer Inc.
14.10. Amgen
14.11. Celgene Corporation

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

T細胞療法の世界市場の評価：モダリティ別、治療タイプ別、適応症別、エンドユーザー別、地域別、機会、予測（2016年～2030年）

T-Cells therapy Market Assessment, By Modality, By Therapy Type, By Indication, By End-user, By Region, Opportunities and Forecast, 2016-2030F

戦略的な政府投資および民間投資の増加

CAR-T細胞療法の進歩

治療アプローチにおける最新の進歩

COVID-19の影響

目次

第1章 調査手法

第2章 プロジェクトの範囲と定義

第3章 世界のT細胞療法市場に対するCOVID-19の影響

第4章 エグゼクティブサマリー

第5章 世界のT細胞療法市場の見通し（2016年～2030年）

第6章 世界のT細胞療法市場の見通し：地域別（2016年～2030年）

第7章 市場マッピング（2022年）

第8章 マクロ環境と産業構造

第9章 市場力学

第10章 規制の枠組みとイノベーション

第11章 主要企業情勢

第12章 価格分析

第13章 ケーススタディ

第14章 主要企業の見通し

第15章 戦略的推奨事項

第16章 当社について、免責事項